Keywords: isis, gets, 2m, b-ms, selects, first, pcsk9
Isis gets $2M as B-MS selects first PCSK9 blocker
Article | 14 April 2008
US drug major Bristol-Myers Squibb has selected a compound from its collaboration with Isis Pharmaceuticals, triggering a $2.0-million milestone payment ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
